- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02437500
Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
SERES-016 is a multicenter, expanded-access program (EAP) of SER-109 for subjects with RCDI conducted in the US. Up to approximately 90 subjects are expected to be treated with SER-109, or until SER-109 investigational product is exhausted. Within 3 days after end of antibiotics and on the day preceding SER-109, a bowel cleanse should be administered.
Subjects who meet all the inclusion criteria and none of the exclusion criteria are eligible for participation in the EAP. Each subject (or subject's legally authorized representative) will have to sign an informed consent form (ICF) indicating their consent to participate in the EAP.
Subjects will receive an oral dose of SER-109 in 4 capsules once daily for 3 consecutive days.
Study Type
Expanded Access Type
- Treatment IND/Protocol
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Main Inclusion Criteria:
- Signed informed consent prior to initiation of any EAP-specific procedure or treatment. The subject, or their legally authorized representative, must be willing to provide written informed consent and understand the potential risks and benefits from EAP enrollment and treatment.
- ≥2 episodes of CDI inclusive of the current episode
The CDI recurrence must have met the protocol definition of:
- ≥3 unformed stools per day for 2 consecutive days
- A positive C. difficile stool toxin assay or PCR test
- CDI antibiotic therapy defined as either 10-21 days of vancomycin (125 mg po QID) or fidaxomicin (200 mg po BID). Pulse taper courses are also accepted.
- An adequate clinical response to antibiotic therapy, defined as (<3 unformed stools in 24 hours) for 2 or more consecutive days while on antibiotics.
- The requirement that the subject can be dosed with study drug within 4 days of antibiotic completion.
Main Exclusion Criteria:
- Female subjects who are pregnant, breastfeeding, lactating, or planning to become pregnant during the study.
- Known or suspected toxic megacolon and/or known small bowel ileus.
- Admitted to or expected to be admitted to an intensive care unit.
- Absolute neutrophil count of <500 cells/mm^3.
- Major gastrointestinal surgery (e.g., significant bowel resection or diversion) within 3 months before enrollment (this does not include appendectomy or cholecystectomy), or any history of total colectomy or bariatric surgery (bariatric surgery which does not disrupt the gastrointestinal lumen, i.e., restrictive procedures such as banding, are permitted).
- History of active inflammatory bowel disease (ulcerative colitis, Crohn's disease, microscopic colitis) with diarrhea believed to be caused by active inflammatory bowel disease in the past 3 months.
- Any history of fecal microbiota transplantation (FMT) in the past 3 months.
- Concurrent intensive induction chemotherapy, radiotherapy, or biologic treatment for active malignancy (subjects on maintenance chemotherapy may only be enrolled after consultation with the study medical monitor).
Study Plan
How is the study designed?
Collaborators and Investigators
Sponsor
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SERES-016
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clostridioides Difficile Infection
-
Vedanta Biosciences, Inc.CompletedClostridium Difficile Infection | Clostridium Difficile Infection Recurrence | Clostridium Difficile | CDI | Clostridioides Difficile Infection | Clostridioides Difficile | Clostridioides Difficile Infection RecurrenceUnited States, Canada
-
University of MinnesotaRecruitingRecurrent Clostridioides Difficile Infection | Colonic SurgeryUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingClostridioides Difficile Infection RecurrenceItaly
-
Vedanta Biosciences, Inc.Not yet recruitingClostridium Difficile Infection Recurrence | Recurrent Clostridium Difficile Infection | Clostridium Difficile | Diarrhea Infectious | CDI | Clostridium Difficile Infections | Clostridioides Difficile Infection | C.Difficile Diarrhea | Clostridioides Difficile Infection Recurrence | C. Diff Infection
-
Hellenic Institute for the Study of SepsisCompletedMortality | Clostridioides Difficile Infection | Organ Dysfunction Syndrome | Stool Microbiome | Clostridioides Difficile Infection RecurrenceGreece
-
Christian HvasInnovation Fund DenmarkActive, not recruitingClostridium Difficile Infection | Clostridioides Difficile InfectionDenmark
-
Hanyang University Seoul HospitalPfizer; Korean Center for Disease Control and PreventionUnknownClostridium Difficile Infection
-
Acurx Pharmaceuticals Inc.Active, not recruitingClostridium Difficile InfectionUnited States
-
Summit TherapeuticsCompletedClostridioides Difficile InfectionUnited States, Spain, France, Canada, Belgium, Israel, Chile, Belarus, Latvia, Germany, Romania, Lithuania, Mexico, Czechia, Estonia, Georgia, Peru
-
Summit TherapeuticsCompletedClostridioides Difficile InfectionUnited States, Australia, Greece, Canada, Spain, Brazil, Poland, Korea, Republic of, Argentina, Bulgaria, Hungary, New Zealand, Romania, Russian Federation
Clinical Trials on SER-109
-
Seres Therapeutics, Inc.CompletedClostridioides Difficile InfectionUnited States, Canada
-
Seres Therapeutics, Inc.CompletedClostridium Difficile InfectionUnited States, Canada
-
Seres Therapeutics, Inc.Syneos HealthCompletedClostridium DifficileUnited States
-
RXi Pharmaceuticals, Corp.UnknownHypertrophic ScarUnited States, Honduras
-
Coronado Biosciences, Inc.Unknown
-
Hunan Province Tumor HospitalCompleted
-
RXi Pharmaceuticals, Corp.UnknownAge-related Macular Degeneration | Subfoveal Choroidal Neovascularization | Subretinal Scarring | Subretinal FibrosisUnited States
-
Taiho Pharmaceutical Co., Ltd.TerminatedAdvanced Colorectal CancerUnited States
-
Lytix Biopharma ASCompletedAtopic Dermatitis | Gram-positive, Skin Infections | Mild Eczema/DermatosesHungary
-
RXi Pharmaceuticals, Corp.CompletedHypertrophic ScarUnited States, Honduras